The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2022 | Highlights in GI cancers from SITC 2022
J. Randolph Hecht, MD, University of California, Los Angeles, CA, shares his highlights in gastrointestinal (GI) cancer from the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022), including data on a Phase II trial investigating botensilimab, an Fc-enhanced anti-CTLA-4, in combination with the anti-PD-1, balstilimab, in patients with microsatellite stable colorectal cancer (MSS CRC). Although patients with microsatellite instability-high (MSI-H) CRC have demonstrated significant sensitivity to checkpoint inhibitors, 97% of patients with MSS CRC are irresponsive. The combination of balstilimab with botensilimab demonstrated an overall response rate (ORR) of 22% in patients with MSS colon cancer. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
